Angela Hwang Consulting, P.O. Box 6601, Albany, CA, 94706, USA; MMGH Consulting GmbH, Kuerbergstrasse 1, 8049 Zurich, Switzerland.
Task Force for Global Health, 330 West Ponce de Leon Ave., Decatur, GA, 30030, USA.
Vaccine. 2020 Jul 14;38(33):5372-5378. doi: 10.1016/j.vaccine.2020.05.048. Epub 2020 Jun 4.
The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surveys and interviews relating to GVAP, conducted to inform the immunization strategy for the next decade.
Three surveys and two sets of semi-structured interviews were conducted from 2017 to 2019. Respondents consisted of immunization stakeholders at global, regional, and country levels, and included individuals who had been involved in the development and implementation of GVAP or its monitoring, evaluation and accountability (M&E/A) process; national immunization managers; academics; and personnel from non-governmental organizations and civil society organizations.
The surveys and interviews gave consistent results. They highlighted the value of GVAP in increasing visibility for immunization and the benefits of the GVAP M&E/A framework. The main limitations of GVAP were identified as the limited ownership by countries and other stakeholders leading to incomplete implementation of the strategy and poor accountability for achieving GVAP targets.
These results informed the review of GVAP and the development of its successor strategy, the Immunization Agenda 2030. In addition, these surveys and interviews identified two challenges in assessing the value of GVAP: the need to rely exclusively on stakeholder perspectives and difficulties in attributing benefits. These challenges are inherent in evaluating an over-arching strategy such as GVAP and should be factored into interpretation of the results.
全球疫苗行动计划(GVAP)于 2012 年获得世界卫生大会一致通过,该计划为改善免疫规划制定了一项雄心勃勃的策略。在这十年结束时,已经取得了重大进展,但五项 GVAP 目标中有四项可能无法实现。本报告描述了一组与 GVAP 相关的调查和访谈,旨在为下一个十年的免疫战略提供信息。
从 2017 年到 2019 年进行了三项调查和两组半结构化访谈。受访者包括全球、区域和国家各级的免疫利益相关者,包括参与 GVAP 制定和实施及其监测、评估和问责制(M&E/A)进程的个人;国家免疫管理人员;学者;以及来自非政府组织和民间社会组织的人员。
调查和访谈结果一致。它们强调了 GVAP 提高免疫可见度的价值,以及 GVAP M&E/A 框架的好处。确定 GVAP 的主要限制因素是国家和其他利益攸关方的有限所有权,导致该战略执行不完整,实现 GVAP 目标的问责制薄弱。
这些结果为审查 GVAP 和制定其继任战略——免疫议程 2030 提供了信息。此外,这些调查和访谈确定了评估 GVAP 价值的两个挑战:需要完全依赖利益攸关方的观点和难以归因于利益。这些挑战在评估全球疫苗行动计划等总体战略时是固有的,应在解释结果时考虑到这些挑战。